BRPI1015996A2 - composições farmacêuticas aquosas contendo complexos de borato-poliol - Google Patents

composições farmacêuticas aquosas contendo complexos de borato-poliol

Info

Publication number
BRPI1015996A2
BRPI1015996A2 BRPI1015996A BRPI1015996A BRPI1015996A2 BR PI1015996 A2 BRPI1015996 A2 BR PI1015996A2 BR PI1015996 A BRPI1015996 A BR PI1015996A BR PI1015996 A BRPI1015996 A BR PI1015996A BR PI1015996 A2 BRPI1015996 A2 BR PI1015996A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
compositions containing
aqueous pharmaceutical
containing borate
polyol complexes
Prior art date
Application number
BRPI1015996A
Other languages
English (en)
Inventor
Bhagwati P Kabra
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42364357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015996(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BRPI1015996A2 publication Critical patent/BRPI1015996A2/pt
Publication of BRPI1015996A8 publication Critical patent/BRPI1015996A8/pt
Publication of BRPI1015996B1 publication Critical patent/BRPI1015996B1/pt
Publication of BRPI1015996B8 publication Critical patent/BRPI1015996B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1015996A 2009-06-19 2010-06-17 composição oftálmica de múltiplas doses contendo complexos de borato-poliol. BRPI1015996B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21847209P 2009-06-19 2009-06-19
US61/218,472 2009-06-19
PCT/US2010/038979 WO2010148190A1 (en) 2009-06-19 2010-06-17 Aqueous pharmaceutical compositions containing borate-polyol complexes

Publications (4)

Publication Number Publication Date
BRPI1015996A2 true BRPI1015996A2 (pt) 2016-04-26
BRPI1015996A8 BRPI1015996A8 (pt) 2018-01-09
BRPI1015996B1 BRPI1015996B1 (pt) 2020-08-11
BRPI1015996B8 BRPI1015996B8 (pt) 2021-05-25

Family

ID=42364357

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015996A BRPI1015996B8 (pt) 2009-06-19 2010-06-17 composição oftálmica de múltiplas doses contendo complexos de borato-poliol.

Country Status (26)

Country Link
US (3) US9044484B2 (pt)
EP (4) EP3045164B1 (pt)
JP (3) JP6017956B2 (pt)
KR (1) KR101738502B1 (pt)
CN (2) CN104707145A (pt)
AR (2) AR077126A1 (pt)
AU (1) AU2010262898B2 (pt)
BR (1) BRPI1015996B8 (pt)
CA (1) CA2763778C (pt)
CL (1) CL2010000634A1 (pt)
CY (2) CY1117835T1 (pt)
DK (3) DK3045164T3 (pt)
ES (3) ES2803648T3 (pt)
HR (2) HRP20160953T1 (pt)
HU (2) HUE030435T2 (pt)
LT (1) LT3045164T (pt)
MX (1) MX2011013107A (pt)
PL (3) PL2722035T3 (pt)
PT (3) PT2722035T (pt)
RU (1) RU2563125C2 (pt)
SI (3) SI3045164T1 (pt)
SM (1) SMT201600249B (pt)
TW (1) TWI489997B (pt)
UY (1) UY32709A (pt)
WO (1) WO2010148190A1 (pt)
ZA (1) ZA201108384B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0909738A2 (pt) * 2008-03-17 2015-10-06 Alcon Res Ltd composições farmacêuticas aquosas contendo complexos de boratopoliol
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸-多元醇錯合物之水性藥學組成物
WO2012099142A1 (ja) 2011-01-18 2012-07-26 千寿製薬株式会社 保存効力を有するブロムフェナク水性液剤組成物
CN104039307A (zh) 2011-04-22 2014-09-10 爱尔康研究有限公司 具有包含两种不同粘度增强剂的粘度增强体系的眼用组合物
EP3045163A1 (en) 2011-04-22 2016-07-20 Alcon Research, Ltd. Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
CA2899342C (en) 2013-02-01 2021-09-21 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
AU2014212274A1 (en) 2013-02-01 2015-08-13 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
BR112016003692B1 (pt) 2013-08-20 2022-02-08 3M Innovative Properties Company Complexo poliéter boro-silano
WO2017217450A1 (ja) * 2016-06-15 2017-12-21 千寿製薬株式会社 眼科用医薬製品
JP6247430B1 (ja) * 2016-06-15 2017-12-13 千寿製薬株式会社 眼科用医薬製品
CN106237337B (zh) * 2016-08-05 2019-11-08 河南中帅医药科技股份有限公司 一种液体药物制剂用防腐组合物
GR1009419B (el) * 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
JP7413040B2 (ja) 2018-02-21 2024-01-15 三菱重工サーマルシステムズ株式会社 スクロール流体機械及びその設計方法
EP3866790A4 (en) 2018-10-15 2022-08-03 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES
EP3870170B1 (en) 2018-10-26 2026-02-25 Opus Genetics, Inc. Treatment of presbyopia and mydriasis with phentolamine
KR20220038443A (ko) 2019-07-23 2022-03-28 니콕스 오프탈믹스,아이엔씨. 무균 안과용 수성 플루티카손 프로피오네이트 a형 나노결정 현탁액을 제조하는 방법
EP4142689A1 (en) * 2020-04-29 2023-03-08 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
US11850249B2 (en) 2020-10-05 2023-12-26 Somerset Therapeutics, Llc Methods of efficiently reducing intraocular pressure
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2025174723A1 (en) * 2024-02-12 2025-08-21 Selagine Inc. Ophthalmic composition comprising cethromycin

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
GB2084870B (en) 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5221664A (en) 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
JP3058656B2 (ja) 1990-06-18 2000-07-04 トーメー産業株式会社 コンタクトレンズ用液剤組成物及びそれを用いたコンタクトレンズの洗浄若しくは保存方法
HU212184B (en) 1990-12-27 1996-03-28 Allergan Inc Method and composition for disinfecting contact-lenses
US5460834A (en) 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
JP2873530B2 (ja) * 1991-12-13 1999-03-24 参天製薬株式会社 ニュートン型粘性を示すカルボキシビニルポリマー含有点眼液基剤
ATE300936T1 (de) 1992-05-06 2005-08-15 Alcon Lab Inc Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5320843A (en) 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
CA2088927A1 (en) 1993-02-11 1994-08-12 Donald Skeffington Preservative system for vitamin e aqueous solution
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
TW274516B (pt) 1993-11-12 1996-04-21 Ciba Geigy Ag
AU3070395A (en) 1994-07-22 1996-02-22 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US5603929A (en) 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US6024954A (en) 1994-12-12 2000-02-15 Allergan Compositions and methods for disinfecting contact lenses and preserving contact lens care products
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
BR9607808A (pt) 1995-03-20 1998-07-07 Unilever Nv Composição para limpeza da pele e processo para realçar o efeito antimicrobiano das formulações para limpeza da pele
US5683993A (en) 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
HU225329B1 (en) 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
WO1998011867A1 (en) 1996-09-20 1998-03-26 Warner-Lambert Company Oral compositions containing a zinc compound
US5820822A (en) 1996-10-25 1998-10-13 Kross; Robert D. Antimicrobial composition and method of use
JPH10130156A (ja) * 1996-10-30 1998-05-19 Teika Seiyaku Kk 点眼剤組成物
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
ATE326983T1 (de) 1996-12-13 2006-06-15 Alcon Lab Inc Aminoalkohole enthaltende ophthalmische zusammensetzungen
US5858346A (en) 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6265444B1 (en) * 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6034043A (en) 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6166012A (en) 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
CA2430127C (en) 2000-11-29 2010-04-20 Alcon Inc. Aqueous disinfecting system comprising a microbicide and 1,3-bis(tris[hydroxymethyl]methylamino)propane
AR035509A1 (es) 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
JP4844706B2 (ja) * 2001-03-12 2011-12-28 ライオン株式会社 眼科用組成物
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
JP4863589B2 (ja) 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
TWI322828B (en) 2002-12-23 2010-04-01 Alcon Inc Use of multifunctional surface active agents to clean contact lenses
EP1586316B1 (en) * 2003-01-21 2008-04-30 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
AU2004305535A1 (en) 2003-12-09 2005-07-07 Alcon, Inc. Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions
JP4644682B2 (ja) 2003-12-09 2011-03-02 アルコン、インコーポレイテッド 水性組成物の抗微生物活性を強化するためのビスアミンの使用
CA2545947A1 (en) 2003-12-11 2005-07-07 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20050214382A1 (en) 2004-03-29 2005-09-29 Erning Xia Zinc preservative composition and method of use
JP2008515982A (ja) * 2004-10-13 2008-05-15 メルク エンド カムパニー インコーポレーテッド 高眼圧症を治療するための眼科組成物
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US20070212420A1 (en) 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US20070297990A1 (en) 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition
WO2008002118A1 (es) * 2006-06-27 2008-01-03 Arturo Jimenez Bayardo Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
ZA200901164B (en) * 2006-09-21 2010-06-30 Alcon Res Ltd Self preserved aqueous pharmaceutical compositions
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
CN101522171A (zh) 2006-09-28 2009-09-02 爱尔康研究有限公司 自身防腐的水性药物组合物
WO2008052037A2 (en) 2006-10-24 2008-05-02 Alcon Research, Ltd. Packaging materials for formulations containing 2-pyrrolidone derivatives
WO2008052031A2 (en) 2006-10-24 2008-05-02 Alcon Research, Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
US7705112B2 (en) 2007-04-17 2010-04-27 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods
BRPI0909738A2 (pt) * 2008-03-17 2015-10-06 Alcon Res Ltd composições farmacêuticas aquosas contendo complexos de boratopoliol
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
US7999064B2 (en) 2009-04-23 2011-08-16 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods and associated formulations
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸-多元醇錯合物之水性藥學組成物

Also Published As

Publication number Publication date
DK3045164T3 (da) 2020-07-13
HUE049477T2 (hu) 2020-09-28
DK2722035T3 (en) 2016-08-01
JP2016183198A (ja) 2016-10-20
ES2584858T3 (es) 2016-09-29
CL2010000634A1 (es) 2011-03-11
UY32709A (es) 2010-12-31
US9421265B2 (en) 2016-08-23
HUE030435T2 (en) 2017-05-29
HK1194007A1 (en) 2014-10-10
JP2012530712A (ja) 2012-12-06
MX2011013107A (es) 2012-01-20
US20160324967A1 (en) 2016-11-10
EP2442790B1 (en) 2014-03-26
PT2722035T (pt) 2016-08-02
AR077126A1 (es) 2011-08-03
EP3045164A1 (en) 2016-07-20
EP2722035B1 (en) 2016-04-27
HK1163521A1 (en) 2012-09-14
JP2014198729A (ja) 2014-10-23
KR101738502B1 (ko) 2017-05-22
RU2563125C2 (ru) 2015-09-20
ES2461617T3 (es) 2014-05-20
CN102802604B (zh) 2016-02-10
PT2442790E (pt) 2014-05-12
PT3045164T (pt) 2020-07-14
SI2442790T1 (sl) 2014-05-30
TWI489997B (zh) 2015-07-01
PL2442790T3 (pl) 2014-08-29
CN104707145A (zh) 2015-06-17
BRPI1015996B1 (pt) 2020-08-11
KR20120028390A (ko) 2012-03-22
HRP20200979T1 (hr) 2020-10-16
PL3045164T3 (pl) 2020-10-19
PL2722035T3 (pl) 2016-11-30
EP3437634A1 (en) 2019-02-06
DK2442790T3 (da) 2014-04-14
CY1123120T1 (el) 2021-10-29
JP6017956B2 (ja) 2016-11-02
CA2763778A1 (en) 2010-12-23
WO2010148190A1 (en) 2010-12-23
US20150224196A1 (en) 2015-08-13
AU2010262898A1 (en) 2011-12-15
LT3045164T (lt) 2020-07-27
US9044484B2 (en) 2015-06-02
SI2722035T1 (sl) 2016-09-30
AR122017A2 (es) 2022-08-03
BRPI1015996B8 (pt) 2021-05-25
EP2442790A1 (en) 2012-04-25
TW201100103A (en) 2011-01-01
RU2012101782A (ru) 2013-07-27
ES2803648T3 (es) 2021-01-28
US20100324031A1 (en) 2010-12-23
ZA201108384B (en) 2013-01-30
CA2763778C (en) 2016-02-02
AU2010262898B2 (en) 2015-02-12
EP2722035A1 (en) 2014-04-23
SI3045164T1 (sl) 2020-08-31
CN102802604A (zh) 2012-11-28
CY1117835T1 (el) 2017-05-17
SMT201600249B (it) 2016-08-31
EP3045164B1 (en) 2020-04-15
BRPI1015996A8 (pt) 2018-01-09
HRP20160953T1 (hr) 2016-10-07

Similar Documents

Publication Publication Date Title
BRPI1015996A2 (pt) composições farmacêuticas aquosas contendo complexos de borato-poliol
BRPI0909738A2 (pt) composições farmacêuticas aquosas contendo complexos de boratopoliol
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
DK2395834T3 (da) Natriumnitrit-holdige farmaceutiske sammensætninger
LT3061445T (lt) Labai koncentruotos farmacinės kompozicijos
IT1394860B1 (it) Composti farmaceutici
BRPI1012539A2 (pt) composições farmacêuticas
SMT201700095B (is) Composizioni farmaceutiche per inalazione
EP2451274A4 (en) Pharmaceutical compositions
SMT201400069B (it) Formulazione farmaceutica
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
BRPI1015939A2 (pt) composição farmacêutica
IT1394400B1 (it) Composizioni farmaceutiche
BRPI0922653A2 (pt) preparação farmacêutica
IT1393930B1 (it) Composti farmaceutici
BR112012003149A2 (pt) composição farmacêutica
BR112012001340A2 (pt) composições farmacêuticas
BRPI1006076A2 (pt) composicoes farmaceuticas
IT1395724B1 (it) Composti farmaceutici
EP2488175A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI1008983A2 (pt) formulação farmacêutica
IT1396951B1 (it) Composti farmaceutici
DOP2009000016A (es) Composicion farmaceutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALCON RESEARCH, LLC (US)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/00 , A61K 31/335 , A61K 31/52 , A61K 31/542 , A61K 47/02 , A61K 47/10 , A61K 47/18 , A61K 47/32

Ipc: A61K 47/18 (2017.01), A61K 31/498 (2006.01), A61K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF